These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 32561954)

  • 1. Multiple ipsilateral femoral stress fractures in a patient taking denosumab for osteoporosis-a case report.
    Piponov HI; Goldstein JM; Eisenberg GM
    Osteoporos Int; 2020 Nov; 31(11):2263-2267. PubMed ID: 32561954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atypical femoral fracture in a bisphosphonate-naïve patient on denosumab for osteoporosis.
    Kumar S; Chang R; Reyes M; Diamond T
    Arch Osteoporos; 2022 Oct; 17(1):131. PubMed ID: 36180610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bilateral Atypical Femur Fractures After Denosumab in a Bisphosphonate Naive Patient: A Case Report.
    Goh JKM; Koh JSB; Ng ACM; Png MA; Howe TS
    Calcif Tissue Int; 2022 Jul; 111(1):96-101. PubMed ID: 35132455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bilateral atypical femoral fractures in a patient prescribed denosumab - a case report.
    Thompson RN; Armstrong CL; Heyburn G
    Bone; 2014 Apr; 61():44-7. PubMed ID: 24389366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous bilateral atypical femoral fracture in a patient receiving denosumab: case report and literature review.
    Selga J; Nuñez JH; Minguell J; Lalanza M; Garrido M
    Osteoporos Int; 2016 Feb; 27(2):827-32. PubMed ID: 26501556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MANAGEMENT OF ENDOCRINE DISEASE: Atypical femoral fractures: risks and benefits of long-term treatment of osteoporosis with anti-resorptive therapy.
    Adler RA
    Eur J Endocrinol; 2018 Mar; 178(3):R81-R87. PubMed ID: 29339529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence of bilateral atypical femoral fractures associated with the sequential use of teriparatide and denosumab: a case report.
    Ramchand SK; Chiang CY; Zebaze RM; Seeman E
    Osteoporos Int; 2016 Feb; 27(2):821-5. PubMed ID: 26458389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical fracture of the femur in a patient using denosumab--a case report.
    Schilcher J; Aspenberg P
    Acta Orthop; 2014 Feb; 85(1):6-7. PubMed ID: 24460109
    [No Abstract]   [Full Text] [Related]  

  • 9. A probable atypical ulnar fracture in a man receiving denosumab.
    Binkley N; Goel H; Shives E; Krueger D; Hare K
    Bone; 2021 Feb; 143():115726. PubMed ID: 33130001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atypical femoral fractures bilaterally in a patient receiving denosumab.
    Drampalos E; Skarpas G; Barbounakis N; Michos I
    Acta Orthop; 2014 Feb; 85(1):3-5. PubMed ID: 24171686
    [No Abstract]   [Full Text] [Related]  

  • 11. Tibial stress reaction presenting as bilateral shin pain in a man taking denosumab for giant cell tumor of the bone.
    Lim SY; Rastalsky N; Choy E; Bolster MB
    Bone; 2015 Dec; 81():31-35. PubMed ID: 26117225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conservative treatment of recurrent symptoms of an incomplete, atypical femoral fracture associated with glucocorticoid, bisphosphonate, and denosumab therapy in a patient with chronic obstructive pulmonary disease.
    Lai KH; Chiang CY; Yang RS; Yang KC; Wu CC
    Acta Clin Belg; 2019 Oct; 74(5):370-374. PubMed ID: 30336748
    [No Abstract]   [Full Text] [Related]  

  • 13. Atypical Femoral Fractures (AFF) from Bone Remodeling Agents in Patients with Cancer.
    Kordoni M; Rigakos G; Kim YHM; Kaklamanis L; Nikolatou-Galitis O; Hadjiyassemi L; Labropoulos S; Razis E
    Anticancer Res; 2018 Nov; 38(11):6439-6444. PubMed ID: 30396969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.
    Shane E; Burr D; Abrahamsen B; Adler RA; Brown TD; Cheung AM; Cosman F; Curtis JR; Dell R; Dempster DW; Ebeling PR; Einhorn TA; Genant HK; Geusens P; Klaushofer K; Lane JM; McKiernan F; McKinney R; Ng A; Nieves J; O'Keefe R; Papapoulos S; Howe TS; van der Meulen MC; Weinstein RS; Whyte MP
    J Bone Miner Res; 2014 Jan; 29(1):1-23. PubMed ID: 23712442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab and atypical femoral fractures.
    Aspenberg P
    Acta Orthop; 2014 Feb; 85(1):1. PubMed ID: 24171676
    [No Abstract]   [Full Text] [Related]  

  • 16. [Atypical femoral fractures in bisphosphonate therapy].
    Ballaschk A; Kalaitzis N; Röpke M; Piatek S
    Unfallchirurg; 2015 Jan; 118(1):88-91. PubMed ID: 24352201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bilateral femur fractures associated with short-term bisphosphonate use.
    Rifai A; Pourtaheri S; Carbone A; Callaghan JJ; Stadler CM; Record N; Issa K
    Orthopedics; 2015 Feb; 38(2):e139-42. PubMed ID: 25665120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective Review of Atypical Femoral Fracture in Metastatic Bone Disease Patients Receiving Denosumab Therapy.
    Yang SP; Kim TW; Boland PJ; Farooki A
    Oncologist; 2017 Apr; 22(4):438-444. PubMed ID: 28275116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical femoral fracture in a patient treated with denosumab.
    Khow KS; Yong TY
    J Bone Miner Metab; 2015 May; 33(3):355-8. PubMed ID: 24996528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression of atypical femur stress fracture after discontinuation of bisphosphonate therapy.
    Gu KD; Ettinger B; Grimsrud CD; Lo JC
    Osteoporos Int; 2021 Oct; 32(10):2119-2123. PubMed ID: 33914104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.